Search - tctmd.com

Displaying 1 - 20 of 105

Sort: Relevancy | Date

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

L.A. McKeown

October 29, 2024

Presentation TCT 2024

Drug Delivery Technologies for the SFA: Where are We Now After the Paclitaxel Scare?

Presenter: Sahil Parikh

October 28, 2024

Presentation TCT 2024

Atherectomy/IVL: What is Optimal Lesion Preparation for the SFA?

Presenter: Ehrin Armstrong

October 28, 2024

Presentation TCT 2024

Scaffolds for the SFA: Will We Ever Have Anything Better Than Nitinol?

Presenter: Lawrence Garcia

October 28, 2024

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

L.A. McKeown

October 24, 2023

Presentation TCT 2021

Case Presentation: Long Segment SFA Occlusion

Presenter: Mohammad Ansari

November 06, 2021

Presentation TCT 2020

TCT 648: Treatment of a SFA Hemorrhage at Antegrade Perfusion Sheath Site and Successful Reperfusion of an Ischemic Leg Secondary to ECMO Sheath Obstruction with Perfusion Sheath Placement in the Distal Anterior Tibial Artery

Presenter: Chris Rosse

October 14, 2020

Presentation TCT 2020

TCT 545: Transcollateral Intra-Arterial Retrograde Ostial SFA CTO Recanalization for CLI

Presenter: Sehrish Memon

October 14, 2020

News Conference News TCT 2019

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

L.A. McKeown

September 28, 2019

Presentation TCT 2019

Sustained Limus Release-Designed Drug-Eluting Balloons: Is This the Solution for the Potential Increased Mortality With Paclitaxel Devices When Treating the SFA?

Presenter: Thomas Zeller

September 27, 2019

Presentation TCT 2019

Drug-Eluting Technologies for SFA Disease: Industry’s Perspective and a Pathway Forward

Presenter: Ian Meredith AM

September 26, 2019

Presentation TCT 2019

Is Paclitaxel-Related Mortality From SFA Drug-Eluting Technologies Biologically Plausible?

Presenter: Elazer Edelman

September 26, 2019

Presentation TCT 2019

Paclitaxel-Coated Devices for SFA Disease: An Independent, Patient-Level Meta-Analysis and Other Emerging Data

Presenter: Krishna Rocha-Singh

September 26, 2019

Presentation TCT 2019

New Insights From Our Meta-Analysis of Paclitaxel-Coated Device Randomized Trials for SFA Disease (And the Response It Has Generated)

Presenter: Konstantinos Katsanos

September 26, 2019

Presentation TCT 2019

Intravascular Ultrasound Supported Endovascular Therapy in SFA Disease: 12-Month Results From the IVORY Study

Presenter: Osamu Iida

September 26, 2019

Presentation TCT 2019

Emerging Drug-Free Platforms for the SFA: Can We Do Better Off Drugs?

Presenter: William Gray

September 26, 2019

Presentation TCT 2019

Deciphering the FDA Guidance

Presenter: Mehdi Shishehbor

September 26, 2019

Presentation TCT 2019

State of the Art Lecture: Novel Drug Delivery Technologies for the SFA

Presenter: Juan Granada

September 26, 2019

Presentation TCT 2019

Introduction and Session Objectives

Presenter: Sahil Parikh

September 26, 2019

Presentation TCT 2019

My Toughest SFA Case of the Year

Presenter: Subhash Banerjee

September 25, 2019

Advertisement

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

Drug Delivery Technologies for the SFA: Where are We Now After the Paclitaxel Scare?

Atherectomy/IVL: What is Optimal Lesion Preparation for the SFA?

Scaffolds for the SFA: Will We Ever Have Anything Better Than Nitinol?

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

Case Presentation: Long Segment SFA Occlusion

TCT 648: Treatment of a SFA Hemorrhage at Antegrade Perfusion Sheath Site and Successful Reperfusion of an Ischemic Leg Secondary to ECMO Sheath Obstruction with Perfusion Sheath Placement in the Distal Anterior Tibial Artery

TCT 545: Transcollateral Intra-Arterial Retrograde Ostial SFA CTO Recanalization for CLI

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

Sustained Limus Release-Designed Drug-Eluting Balloons: Is This the Solution for the Potential Increased Mortality With Paclitaxel Devices When Treating the SFA?

Drug-Eluting Technologies for SFA Disease: Industry’s Perspective and a Pathway Forward

Is Paclitaxel-Related Mortality From SFA Drug-Eluting Technologies Biologically Plausible?

Paclitaxel-Coated Devices for SFA Disease: An Independent, Patient-Level Meta-Analysis and Other Emerging Data

New Insights From Our Meta-Analysis of Paclitaxel-Coated Device Randomized Trials for SFA Disease (And the Response It Has Generated)

Intravascular Ultrasound Supported Endovascular Therapy in SFA Disease: 12-Month Results From the IVORY Study

Emerging Drug-Free Platforms for the SFA: Can We Do Better Off Drugs?

Deciphering the FDA Guidance

State of the Art Lecture: Novel Drug Delivery Technologies for the SFA

Introduction and Session Objectives

My Toughest SFA Case of the Year

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content